Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects

Immunologie und Immuncheckpoint-Inhibition des Ovarialkarzinoms – aktuelle Aspekte

Author
Holger Bronger¹,²

Affiliations
1 Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München, München, Germany
2 Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partnerstandort München und Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany

Key words
ovarian cancer, immune checkpoint blockade, PD-L1, tumour-infiltrating lymphocytes

Schlüsselwörter
Ovarialkarzinom, Immuncheckpoint-Blockade, PD-L1, tumorinfiltrierende Lymphozyten

ABSTRACT
In the last decade immunotherapies such as immune checkpoint blockade (ICB) against the PD-1/PD-L1 system have revolutionised the treatment of numerous entities. To date, ovarian cancer has benefited very little from this success story. Possible causes include a rather low mutational burden compared to other tumour types, inadequate presentation of (neo-)antigens, and increased infiltration with immunosuppressive immune cells such as regulatory T cells and tumour-associated macrophages. In the clinical trials completed to date, the response rates to PD-1/PD-L1 checkpoint inhibitors have therefore been disappointingly low as well, although isolated long-term remissions have also been observed in ovarian cancer. The task now is to find suitable predictive biomarkers as well as to identify combination partners for ICB therapy that can increase the immunogenicity of ovarian cancer or overcome immunosuppressive resistance mechanisms. This paper provides an overview of the immune milieu in ovarian cancer, its impact on the effect of ICB, and summarises the clinical trial data available to date on ICB in ovarian cancer.

ZUSAMMENFASSUNG
Immuntherapien wie die Immuncheckpoint-Blockade (ICB) gegen das PD-1/PD-L1-System haben in der letzten Dekade die Behandlung zahlreicher Entitäten revolutioniert. Das Ovarialkarzinom ist bislang von diesen Erfolgen weitestgehend ausgenommen. Mögliche Ursachen liegen in einer gegenüber anderen Tumorarten vergleichsweise niedrigen Mutationslast, einer unzureichenden Präsentation von (Neo-)Antigenen sowie einer erhöhten Infiltration mit immunsuppressiven Immunzellen wie regulatorischen T-Zellen oder tumorassoziierten Makrophagen. In den bisher durchgeführten klinischen Studien waren die Ansprechraten auf Inhibitoren des PD-1/PD-L1-Checkpoints dementsprechend auch enttäuschend niedrig, jedoch zeigen sich auch beim Ovarialkarzinom vereinzelte Langzeitremissionen. Es gilt nun, einerseits geeignete prädiktive Biomarker zu finden, andererseits Kombinationspartner für die ICB-Therapie zu identifizieren, welche die Im-
Introduction

Although concepts on the interaction of tumours with the immune system were developed as early as the 19th century [1], for much of the 20th century cancer research focused solely on the tumour cell itself. The success of this era was evident in chemotherapy, developed since the 1940s, and targeted therapy, developed since the 1990s. The surroundings of the tumour cell, the tumour microenvironment, and thus also the immune composition of a tumour, became the focus of research rather late [2]. Over the last forty years, however, the functional understanding of the interaction of the immune system with the tumour has expanded considerably, notably culminating in the breakthrough of immuno-oncology with the success of inhibitors against the immune checkpoint proteins CTLA-4 and PD-1/PD-L1 in malignant melanoma and other immunogenic tumours. In the long term, immuno-oncology promises to come closest to the ideal of personalised therapy. Interestingly enough, a substantial part of the effect of traditional chemotherapeutics and targeted substances also seems to arise from a stimulation of the tumour-suppressive immune response [3]. At present the landscape of oncological studies is dominated by immuno-oncological studies, especially those on immune checkpoint inhibition.

However, ovarian cancer has seen little of the success of immuno-oncology. Immunological treatment approaches such as the administration of inflammatory cytokines, adoptive T cell transfer, and vaccinations against common tumour antigens have only been partially successful and have not yet made it into routine clinical practice [4]. Most recently, the IMAgyn050 trial, which was reported negative and tested the administration of the anti-PD-L1 antibody atezolizumab in addition to standard first-line therapy in advanced ovarian cancer, demonstrated that a “crushing victory” in immune checkpoint inhibition can no longer be expected [5]. It also remains to be seen whether the current trials in recurrent ovarian cancer will confirm a better effect of ICB monotherapy, since the tumour tends to be immunologically “burnt out” in later lines of therapy. However, since in the phase I/II trials conducted to date long-term remissions have indeed been observed in some patients, there is still reason for optimism in ovarian cancer [7,8].

Preclinically and clinically, therefore, three avenues are currently being explored: first, the mechanisms of immune escape in ovarian cancer need to be further elucidated, with an understanding of the immune milieu in ovarian cancer being absolutely essential. Second, this may also help in developing appropriate predictive biomarkers that can identify the (still small) population of patients actually benefiting from immune checkpoint inhibition. And third, ongoing trials currently recruiting are testing which combination of partners can be used to induce a substantial immune response against ovarian cancer, which may then be enhanced by ICB (e.g., PARP inhibitors).

This review therefore aims to provide an overview of the current understanding of the interaction of the immune system with epithelial ovarian cancer, which in turn is a prerequisite for understanding the effect, as well as the failure, of immunotherapies. The second part then provides an overview of the clinical trial results of immune checkpoint blockade to date.

The Immunogenicity of Ovarian Cancer: Mutational Burden, Tumour Antigens and Immune Infiltration

The ability of the immune system to fight tumour growth, and thus the success of immune checkpoint therapies, depends on several factors: intrinsic properties of the tumour itself such as mutational burden and (neo-)antigen presentation, immune cellular factors such as the extent and composition of the immune infiltrate within the tumour, and immune modulating qualities of the tumour microenvironment, e.g. the expression of immune checkpoint proteins. The time related dynamics of these factors in the course of the malignant disease further add to the complexity. The traditional concept is based on three succinct phases in which the immune system can initially fight the tumour effectively (elimination), but then weakly immunogenic tumour cell clones assert themselves under the selection pressure exerted in this way (equilibrium), and the tumour can finally escape completely from the control of the immune system (escape) [9]. These processes are also significantly affected by the systemic therapies.

In terms of the tumour mutational burden (TMB), ovarian cancer is in the lower midfield of all entities [10,11]. While malignant melanoma has mutation rates of about 14–47 mutations/Mb, most ovarian cancers exhibit only about 1–3.5 mutations/Mb [10,12]. Although some papers report higher mutation rates (20–40 mutations/Mb), only 1.3% of these mutations were even detected by autologous tumour-associated T cells [13]. TMB correlates with the number of neoantigens and the response to immune checkpoint blockade [14]. In addition, however, this also requires infiltration with appropriate immune effector cells. A recent paper studying these two factors (TMB, T cell signature) in numerous types of cancer revealed that (serous) ovarian cancer ranked almost at the bottom of the malignancies studied [15]. Interestingly enough, serous ovarian carcinomas with high T cell infiltration demonstrate a significantly lower clonal diversity and a lower neoantigen load, indicating that effective immuno-editing also takes place in serous ovarian carcinoma, i.e. effectively combating the majority of tumour cells, but also resulting in the selection of fewer, non-immunogenic tumour cell clones [16]. As TCGA analysis has shown, other mutations apart from p53 mutations are not very common in general [17].

Bronger H. Immunology and Immune... Geburtsch Frauenheilk 2021; 81: 1128–1144 | © 2021. The author(s).
On the other hand, the low TMB is accompanied by a rather frequent expression of tumour antigens, especially cancer testis antigens (CTAs), against which a specific T cell response is often detected in vitro in ovarian cancer [18]. Nevertheless, antibody therapies against such antigens have failed in vivo, including against CA 125, which appears to be one of the most strongly presented immunogenic antigens in ovarian cancer [19–21].

Another decisive factor determining tumour immunogenicity is immune infiltration. Tumour-infiltrating lymphocytes (TILs) as a prognostic marker in ovarian cancer were identified more than 30 years ago [22, 23]. Further evidence of the immunogenicity of ovarian cancer comes from work developing molecular classifications of serous cancer based on genomic studies. Each of these trials was able to define an “immunoreactive subtype” based on the increased expression of genes, for example associated with IFN signalling, which demonstrated the best prognosis in all trials as well as in a meta-analysis [17, 24–26].

All in all, the immunogenicity of ovarian cancer therefore seems to be quite weak.

**The Cellular Immune Milieu in Ovarian Cancer**

Immune cells can both promote and inhibit tumour growth in ovarian cancer (Fig. 1). The most important and best-studied immune cell populations in ovarian cancer are briefly presented below in terms of their effect on immune checkpoint therapy.

**T cells (effector cells)**

Collectively, T cells form the cornerstone of adaptive anti-tumour response and undoubtedly represent the most studied immune cell population in ovarian cancer. Ultimately, this includes various cell groups that can have both tumour-suppressive (T helper cells, cytotoxic T cells) and tumour-promoting (regulatory T cells, see below) qualities. They all have in common the surface marker

---

**Fig. 1** Cellular components of the immune milieu in ovarian cancer and selected important interaction mechanisms. CD8-positive cytotoxic T cells and natural killer cells are crucial mediators of the anti-tumour response in ovarian cancer. They are supported in different ways by dendritic cells, CD4-positive T helper cells and M1 macrophages. M2 macrophages and MDSCs, on the other hand, lead to immunosuppression and activation of regulatory T cells, e.g. through the release of IL-10 and TGF-β, which in turn can inhibit the function of other tumour-suppressive T cells. Details and other mechanisms in the main body of the text.
CD3, which defines this cell type and which has been identified early on as a strong prognostic marker in ovarian cancer [23]. Since the aggregate of all CD3-positive T cells also contains FOXP3-positive regulatory T cells, subsequent studies established CD8, a characteristic receptor of cytotoxic T cells, as an even more robust prognostic marker [27–31]. The CD8/FOX3 ratio, which takes into account the contrasting functions of cytotoxic T cells and regulatory T cells, is just as indicative. While most ovarian cancers contain immune cells in the tumour stroma, intratumoural T cells are found in only about half of all cases; they, in turn, have a stronger prognostic significance and therefore seem to be functionally more important [28]. CD4-positive T helper cells also correlate with better survival, especially the CD4+CD25+FOXP3+ cells, as CD25 is important for T cell expansion and activation [32–34]. Additional roles of CD4-positive T cells include CCL5-mediated recruitment of dendritic cells, which in turn prime CD8-positive cytotoxic T cells [35].

Against the background of these observations, adequate infiltration of the tumour with T cells is not only functionally and prognostically significant, but also represents a basic prerequisite for the success of immunotherapies such as immune checkpoint blockade [36,37]. This recruitment of T cells is mediated by chemokines binding the corresponding chemokine receptors on the surface of the immune cells and chemotactically attracting them to the tumour. Such a function has been demonstrated in ovarian cancer especially for the CXCR3 ligands CXCL9 and CXCL10 [38,39], but also for CCL21/22 [23] as well as CCL2, CCL4 and CCL5 [40].

The CXCR3 chemokine system plays a special role in solid tumours [41,42]. We demonstrated for the first time in humans that overexpression of the CXCR3 chemokines CXCL9 and CXCL10 is associated with increased infiltration of CD3-positive T cells and significantly improved survival in high-grade serous ovarian cancer (HGSOC) [38]. While we found the strongest expression in the tumour cells themselves, other groups localise these chemokines more in the macrophages and dendritic cells [39]. Our observations at the protein level were later confirmed by numerous other groups at the gene level as well: in particular, in the immunoreactive subtype of HGSOC, which has the best prognosis of all molecular subtypes, CXCR3 chemokines were the most upregulated genes [25,26,39]. CXCL9 was also the most upregulated gene in a comparison of regressed versus progressive metastases in a patient with high-grade serous ovarian cancer [43]. In a recent paper by the OTA consortium, which identified a prognostic signature from 513 genes in HGSOC, once again CXCL9 was one of the five genes with the highest prognostic significance [44]. This work suggests a central role for the CXCR3 chemokine system in establishing or maintaining effective tumour-suppressive immune response. CXCR3 chemokines are also necessary for the success of PD-1/PD-L1 checkpoint inhibition and are involved in the immunomodulating activity of PARP inhibitors in ovarian cancer [39,45,46]. They can be induced not only by PARP inhibitors but also by cyclooxygenase inhibitors, which has led to the use of COX inhibitors as adjuvants in immune checkpoint inhibitor studies [32,38,47].

Regulatory T cells (Treg)

Physiologically, regulatory T cells inhibit an exuberant immune response by suppressing the activities of T effector cells, B cells, macrophages, and NK cells [48]. Tumours can thus exploit Treg for immune escape. Treg are possibly commonly found in tumours because they suppress immune responses triggered primarily by self-antigens, and this correlates with the expression of tumour-associated antigens in the tumour [49].

Immune response inhibition is achieved by the following mechanisms [48,49]: Secretion of immunosuppressive cytokines (IL-10, IL-35 and TGF-β); lysis of target cells by granymes and perforins; interception of free IL-2 via the α-chain of the IL-2 receptor [50] so that it cannot activate CD8+ or NK cells; enzymatic cleavage of extracellular (proinflammatory) ATP into AMP and adenosine (via CD39 and CD73), which in turn suppresses the response of T, B and dendritic cells and macrophages via the A2A adenosine receptor; down-regulation of CD80 and CD86 on dendritic cells by binding to CTLA-4 on Treg.

The expression of the FOX3 transcription factor characterises Treg on the one hand it is important for the differentiation towards Treg on the other hand it is necessary for their suppressive function [51–53]. Its expression may therefore also be used to determine Treg infiltration in tumours [54]. Ovarian cancers appear to have a rather high number of Treg, which may be one reason for the poor response to immune checkpoint therapies [54,56]. Accordingly, in most trials, increased FOX3+ immune infiltration also correlates with a higher tumour stage and poorer prognosis [32,56–61].

Different chemokine systems are thought to be responsible for the chemotactic recruitment of Treg into ovarian cancer. CCL28 is induced by hypoxia in preclinical ovarian cancer models, attracts CCR10-positive Treg and is associated with poor survival [62], CCL22, which can be secreted by macrophages, recruits Treg via the CCR4 receptor [59,60,63]. However, Treg can also enter ovarian cancer via the CXCR3 receptor, which actually directs T effector cells [57]. CXCR3-positive Treg even seem to constitute the major part in ovarian cancer, correlate with the number of CXCR3-positive T effector cells, and inhibit them [64]. We were also able to show that in high-grade serous ovarian cancer the expression of CXCL9 and CXCL10 correlates not only with CD3-positive T cells overall, but also with FOXP3-positive regulatory T cells [38]. However, the strong protective effect of CXCR3 chemokines repeatedly noted in ovarian cancer shows that the net effect favours an enhanced, tumour-suppressive immune response. This is also confirmed by functional studies in syngeneic ovarian cancer mouse models [65].

Basically, there are two approaches to prevent Treg-mediated immune escape, and thus possibly also to improve the effect of immune checkpoint inhibition: depletion of regulatory T cells or their reprogramming to IFN-γ producing, so-called Th1 Treg [49,66–68]. One possibility for selective Treg depletion is the administration of low-dose cyclophosphamide (< 250 mg/m²) [69–71]. However, depletion does not appear to be very promising since the Treg quickly return and other T effector populations are usually suppressed as well [49]. However, reprogramming into an IFN-γ producing Th1 phenotype may succeed through CTLA-4 block-
ade, which could be a suitable combination partner for PD-1/PD-L1 inhibition in ovarian cancer [72].

**Tumour-associated macrophages (TAMs)**

Macrophages are a heterogeneous group of myeloid cells and represent major type of immune cells in the ovarian cancer microenvironment, and may even exceed the number of tumor cells [73]. Tumour-associated macrophages (TAMs) either arise from immigration of bone-derived bone marrow monocytes or are derived from tissue-resident macrophages [74]. In analogy to the Th1/Th2 phenotypes of the T cell response, the tumour-suppressive M1 differentiation status is fundamentally distinguished from the tumour-promoting M2 activation status [75]. M1 macrophages may be activated by classical IFN-γ and produce proinflammatory cytokines such as IL-12, TNF-α and IL-23 and tumour-suppressive chemokines such as CXCL9 and CXCL10 [39, 76]. Redifferentiation into an M1 phenotype also appears to be part of the effect of chemotherapies, e.g., trabectedine or paclitaxel [77, 78]. However, the bulk of TAMs are present in an M2 activation state, both in tumour samples from ovarian cancer patients and in preclinical models. This may be because the tumour cells themselves are able to polarise TAMs into an M2 phenotype [79]. CD163, CD204, CD206, and IL-10 are markers of an M2 phenotype [73]. Accordingly, increased levels of CD163 (or CD163-positive macrophages) in the ascites, blood and also in the tumour correlate with a higher tumour stage and a poorer prognosis [80–82]. On the other hand, several trials have found a correlation between an increased M1/M2 ratio and improved survival in ovarian cancer [82].

M2 macrophages result in immunosuppression and increased tumour growth via various mechanisms. They secrete different growth factors such as VEGF, EGF, TGF-β, and HGF, thereby promoting angiogenesis, EMT, spheroid formation, and transcoelomic metastasis [83–85]. Secretion of these factors correlates with recurrence frequency, metastasis, chemoresistance, and poor survival in ovarian cancer [84, 85]. Effective anti-tumour T cell response may also be inhibited in different ways by M2-TAMs: they induce the maturation of regulatory T cells by TGF-β and promote their recruitment into the tumour by CCL22 [56]. Tregs, on the other hand, promote the secretion of IL-6 and IL-10 by TAMs, leading to autocrine upregulation of the immune checkpoint B7-H4 in macrophages [60]. B7-H4 can block T cell function [60, 86, 87]. The expression of PD-L1 by macrophages can also contribute to immune escape.

Given this mode of action of M2-TAMs and their abundance in ovarian cancer, it is quite conceivable that they are an important resistance factor to PD-1/PD-L1-targeted checkpoint blockade [88]. Conversely, M1 macrophages can contribute to the success of anti-PD-1/PD-L1 therapy via the secretion of CXCL9 [89]. Macrophage-depleting therapies and those allowing polarisation into an M1 phenotype could therefore be interesting combination partners in ICB [88, 90]. Options for TAM suppression that already work in the preclinical setting and the resulting improvement in ICB include blockade of the colony-stimulating factor 1 receptor (CSF1R) and CCL2 inhibition [91–93].

**Other types of immune cells**

Although other immune cells such as natural killer cells, dendritic cells, and myeloid-derived suppressor cells (MDSCs) certainly play an important role in ovarian cancer, their impact on the success or failure of immune checkpoint blockade is less obvious. Their role in ovarian cancer has recently been summarised elsewhere [94]. Preclinical studies also on ovarian cancer suggests that these cell types, rather than the tumour cells, may be crucial for PD-1/PD-L1-mediated T cell inactivation – a process that may not take place in the tumour at all, but in the draining lymph nodes [95, 96].

**The PD-1/PD-L1 Immune Checkpoint in Ovarian Cancer**

The expression of the immune checkpoint protein PD-L1 in the microenvironment of ovarian cancer provides the rationale for the use of appropriate inhibitory antibodies. In immunocompetent ovarian cancer mouse models, tumour growth was inhibited by inhibitors against PD-1 or PD-L1 [97, 98].

PD-L1 expression was initially studied mostly in tumour cells. In particular, while previous reports showed a significant correlation of PD-L1 tumour cell expression with poor survival [28, 97, 99], other groups demonstrated just the opposite, correlating PD-L1 with improved immune infiltration and prolonged survival [100–104]. This may be explained by a general increase in IFN-γ response in these tumours as IFN-γ on the one hand delivers an effective anti-tumour response, on the other hand it is a very potent inducer of PD-L1 expression in ovarian cancer cells [97, 100]. This is in line with the observation that PD-L1 expression is particularly strong in the immunoreactive subtype of serous ovarian cancer, whose most highly expressed genes are induced primarily by IFN-γ [26, 105]. The heterogeneity of the study populations, different staining techniques and methods of analysis may help explain these discrepant reports on the prognostic significance of PD-L1 in ovarian cancer.

There are also different claims regarding the main location of PD-L1 in the TME: while PD-L1 expression has traditionally been studied in tumour cells [28], TAMs also appear to be a major site of PD-L1 location [102]. Functionally, PD-L1 on these myeloid cells may be significantly more important than tumour cell PD-L1 in suppressing T cell response. This is suggested by preclinical studies, also in ovarian cancer models [95, 96].

PD-L1-positive tumours are most commonly found among serous carcinomas, significantly more so than in clear cell, mucinous and endometrioid cancers [102, 104]. This is somewhat surprising, as clear cell cancers exhibit the best response to PD-1/PD-L1 checkpoint inhibition in current clinical trials, albeit with small case numbers (see below), and illustrates once again that PD-L1 expression per se is not a good predictive marker. BRCA1/2 mutation status did not result in a difference in PD-L1 expression [104].
Effect of Cytotoxic Systemic Therapy, Surgery and BRCA Mutation Status on the Immune Milieu in Ovarian Cancer

Effect of chemotherapy
Even though the chemotherapeutic agents used in ovarian cancer were originally used purely for their direct cytotoxic properties, their effect also seems to be based, at least in part, on immunomodulatory properties [3]. Thus, the changes in the immune milieu occurring under chemotherapy offer additional opportunities for the correct timing of an immune checkpoint blockade.

Taxanes, for example, suppress regulatory T cells and MDSCs, enhance DC-mediated antigen presentation by upregulating MHC I, and activate NK and T cells as well as DCs through IL-12 and TNF-α secreted by macrophages [106–108]. Platinum salts can generate neoantigens through DNA damage and trigger an IFN type 1 response through activation of the STING signalling pathway, which is also associated with enhanced T cell infiltration, but on the other hand with the induction of PD-L1 [109]. The suppression of regulatory T cells by low-dose cyclophosphamide has already been discussed (see above).

These preclinical findings have been confirmed in patients. The most reliable data in ovarian cancer come from studies of sequential tumour samples under neoadjuvant chemotherapy [110]. Neoadjuvant chemotherapy increases the number of CD4- and CD8-positive tumour-infiltrating T cells [111–115], as well as B cells [111] and dendritic cells [114]. FOXP3-positive regulatory T cells, on the other hand, are downregulated [114], which was a positive prognostic factor in two of the trials [112, 113]. In addition, chemotheraphy in ovarian cancer results in the induction of PD-1/PD-L1 in both tumour and immune cells [111, 113, 116]. This upregulation of checkpoint systems may also be the reason why TILs lose their prognostic value after neoadjuvant chemotherapy [110].

The effect of surgery
The influence of surgery on the immune milieu in ovarian cancer is less well studied than that of chemotherapy. However, it has been shown that primary debulking leads to a reduction in regulatory T cells, a reduction in IL-10 and an improved function of CD8-positive T cells [117]. In addition, there is evidence that the prognostic benefit of chemokines or TIL subsets is particularly strong in patients without residual tumour after surgery [38, 118]. Further studies are certainly necessary, especially with regard to lymphadenectomy and its effect on immunotherapies, since preclinical work, also in ovarian cancer, localise the functionally significant PD-1/PD-L1 interaction not in the tumour itself but rather in the lymph nodes [95].

The effect of homologous recombination defects (e.g., BRCA mutations)
Patients with BRCA-mutated ovarian cancer have a significantly better prognosis than other patients, a fact mainly attributed to a better response to platinum-based chemotherapy. However, this could also have immunological reasons because BRCA-mutated tumours have a higher number of predicted neoantigens, more CD3- and CD8-positive lymphocytes, and stronger PD-L1 expression [27, 119]. The reason for this could be the homologous recombination defect caused by the BRCA mutation, which ultimately results in STING activation and thus induction of an interferon response [120].

Role of Immune Checkpoint Inhibition in the Treatment of Epithelial Ovarian Cancer
No immunotherapy in the strict sense has yet become clinical routine in ovarian cancer. Clinical testing of immune checkpoint inhibitors against the PD-1/PD-L1 system is the most advanced, with the first phase III trials now being completed. These therapies bring along completely novel challenges for the gynaecological oncologist in terms of adverse event management [121]. The most important study outcomes will be discussed below.

Monotherapy with immune checkpoint inhibitors
Due to the good outcomes of immune checkpoint inhibition in other cancers such as malignant melanoma and non-small cell lung cancer, these substances were initially tested as monotherapies in ovarian cancer as well. The rationale was the known expression of checkpoint proteins and their negative prognostic significance in ovarian cancer [28], the strong prognostic impact of tumour-infiltrating T cells [23, 122], a TMB ranking at least in the middle of all entities [11] as well as numerous preclinical studies in animal models (see above). All this suggests an intrinsic immune response against ovarian cancer that can be unleashed by immune checkpoint inhibitors.

Table 1 summarises the important trials. The first trial tested the anti-PD-1 antibody nivolumab in 20 patients with histologically different ovarian cancers at two different doses (1 and 3 mg/kg) [123]. Despite a disappointing overall response rate (ORR) of 15%, four patients demonstrated a long-lasting response (>12 months), two of whom achieved complete remission, including one patient with clear cell ovarian cancer. Interestingly enough, parts of one of the two carcinomas responding to the atezolizumab trial also featured clear cell histology [124]. Both patients in complete remission were dosed with 3 mg/kg. PD-L1 expression was not predictive of response, although the case numbers here were certainly too low.

The KEYNOTE-100 trial, with 376 patients the largest trial reported to date, tested the anti-PD-1 antibody pembrolizumab in a population with, in some cases heavily pretreated, mostly high-grade recurrent serous ovarian cancer [125, 126]. Again, the overall response rate was at disappointing 8.5%, but with some long response intervals. In the subgroup analyses, the response did not correlate with platinum sensitivity or number of prior therapies. However, there was a dependence on PD-L1 expression as determined by the CPS score (Table 1). Patients with a tumour CPS score of ≥10 were found to have a significantly better response (13.8%) than those with a score below 1 (5.0%). However, since the CPS thresholds (≥1, ≥10) were optimized based on a training collective (n = 100), these response rates may have overestimated the actual treatment effect [125].

Bronger H. Immunology and Immune ... Geburtsh Frauenheilk 2021; 81: 1128–1144 | © 2021. The author(s).
Interestingly enough, the clear cell subtype had the best numerical response in the KEYNOTE-100 trial as well (ORR 16%, n = 19). High-grade serous carcinomas responded in 8.5% (n = 283) of cases, and no response was observed in low-grade serous (n = 21) and endometrioid carcinomas (n = 28) [125]. Both patients with clear cell carcinoma in the JAVELIN solid tumour trial also exhibited a response to therapy [127]. Besides the genetic proximity to clear cell renal cell carcinomas [128, 129], one possi-

<table>
<thead>
<tr>
<th>Immune checkpoint inhibitor</th>
<th>Nivolumab</th>
<th>Pembrolizumab</th>
<th>Pembrolizumab</th>
<th>Avelumab</th>
<th>Atezolizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted structure</td>
<td>PD-1</td>
<td>PD-1</td>
<td>PD-1</td>
<td>PD-L1</td>
<td>PD-L1</td>
</tr>
<tr>
<td>Trial</td>
<td>UMIN00000571</td>
<td>NCT02054806</td>
<td>NCT02674061</td>
<td>NCT01772004</td>
<td>NCT01375842</td>
</tr>
<tr>
<td>Dosing</td>
<td>1 mg/kg q14 (n = 10) or 3 mg/kg q14 (n = 10)</td>
<td>10 mg/kg q14</td>
<td>200 mg q21</td>
<td>10 mg/kg q14</td>
<td>Dose ranging trial 9/12 patients: 15 mg/kg</td>
</tr>
<tr>
<td>Phase</td>
<td>Phase II</td>
<td>Phase Ib</td>
<td>Phase II</td>
<td>Phase Ib</td>
<td>Phase Ib</td>
</tr>
<tr>
<td>Design</td>
<td>Single-centre, open</td>
<td>Multicentre, open</td>
<td>Multicentre, open</td>
<td>Multicentre, open</td>
<td>Multicentre, open</td>
</tr>
<tr>
<td>No. of patients</td>
<td>20</td>
<td>26</td>
<td>376 (A: 285, B: 91)</td>
<td>125</td>
<td>12</td>
</tr>
<tr>
<td>Important inclusion criteria</td>
<td>Pt-resistant (&lt; 6 months)</td>
<td>PD-L1 positive</td>
<td>Cohort A: 3–12 months PFI since last Pt</td>
<td>Cohort B: ≥ 3 months PFI since last Pt</td>
<td>75% Pt-resistant (&lt; 3 months)</td>
</tr>
<tr>
<td>Histology</td>
<td>75% serous</td>
<td>15% endometrioid</td>
<td>10% clear cell</td>
<td>46% “adenocarcinoma”</td>
<td>46% high-grade serous</td>
</tr>
<tr>
<td></td>
<td>46% high-grade serous</td>
<td>6% endometrioid</td>
<td>5% clear cell</td>
<td>4% transitional cell carcinoma</td>
<td>7% mutated</td>
</tr>
<tr>
<td></td>
<td>75% high-grade serous</td>
<td>7% endometrioid</td>
<td>6% low-grade serous</td>
<td>7% unspecified</td>
<td>7% unspecified</td>
</tr>
<tr>
<td></td>
<td>74.4% serous</td>
<td>3.2% mucinous</td>
<td>2.4% endometrioid</td>
<td>1.6% clear cell</td>
<td>18.4% unspecified</td>
</tr>
<tr>
<td></td>
<td>80% serous</td>
<td>10% endometrioid</td>
<td>10% mixed endo-metrioid/clear cell</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior therapies</td>
<td>≥ 2 lines (median 4)</td>
<td>73% ≥ 3 lines (median 4)</td>
<td>Cohort A: 1–3 lines (median 3)</td>
<td>65% ≥ 3 lines (median 3)</td>
<td>≥ 2 lines (&gt; 90%)</td>
</tr>
<tr>
<td>PD-L1 testing</td>
<td>TC-IHC (four-level) on primary surgical specimen</td>
<td>CPS ≥ 1</td>
<td>CPS</td>
<td>TC-IHC a.o.</td>
<td>IC-IHC (≥ 5% of tumour)</td>
</tr>
<tr>
<td>ORR</td>
<td>15% (3/20)</td>
<td>12% (3/26)</td>
<td>8.5% (32/376) (A: 8.1%, B: 9.9%)</td>
<td>9.6% (12/125)</td>
<td>22% (2/9)</td>
</tr>
<tr>
<td>CR</td>
<td>10% (2/20)</td>
<td>4% (1/26)</td>
<td>1.9% (7/376)</td>
<td>0.8% (1/125)</td>
<td>11% (1/9)</td>
</tr>
<tr>
<td>ORR (PD-L1 positive)</td>
<td>12.5% (2/16)</td>
<td>12% (3/26)</td>
<td>13.8% (CPS ≥ 10)</td>
<td>No correlation with PD-L1 status</td>
<td>25% (2/8)</td>
</tr>
<tr>
<td>ORR (PD-L1 negative)</td>
<td>25% (1/4)</td>
<td>–</td>
<td>8.0% (CPS ≥ 1)</td>
<td>0% (0/1)</td>
<td>0% (0/1)</td>
</tr>
<tr>
<td>DCR</td>
<td>45%</td>
<td>19% (5/26)</td>
<td>37.2% (140/376)</td>
<td>52% (65/125)</td>
<td>22% (2/9)</td>
</tr>
<tr>
<td>DOR</td>
<td>3.5 months</td>
<td>not met in the 3 responders (&gt; 20.5 months)</td>
<td>10.2 months A: 8.3 months B: 23.6 months</td>
<td>10.4 months</td>
<td>not reported for entire cohort</td>
</tr>
<tr>
<td>PFS</td>
<td>3.5 months (95% CI 1.7–3.9 months)</td>
<td>1.9 months (95% CI 1.8–3.5 months)</td>
<td>2.1 months (A and B)</td>
<td>2.6 months (95% CI 1.4–2.8 months)</td>
<td>2.9 months (95% CI 1.3–5.5 months)</td>
</tr>
<tr>
<td>References</td>
<td>Hamanishi et al. [123]</td>
<td>Varga et al. [168]</td>
<td>Matulonis et al. [125, 169]</td>
<td>Disis et al. [127]</td>
<td>Liu et al. [124]</td>
</tr>
</tbody>
</table>

Abbreviations: CPS = combined positive score, CR = complete remission, DCR = disease control rate, ICB = immune checkpoint blockade, IHC = immunohistochemistry, IC = immune cells, CI = confidence interval, ORR = overall response rate, PD-1 = programmed cell death protein 1, PD-L1 = programmed cell death ligand 1, PFI = platinum-free interval, PFS = progression-free survival, Pt = platinum, TC = tumour cells
ble explanation is increased infiltration of these tumours with CD3-, CD8- and PD-1-positive immune cells as well as increased PD-L1 expression in the tumour cells, especially in tumours with microsatellite instability (MSI) [130]. Thus, MSI testing could be a possible criterion for stratification in clear cell ovarian cancer. The significance of immune checkpoint inhibition in clear cell ovarian cancer is currently being studied in the prospective PEACOCC trial (NCT03425565).

In summary, the monotherapy trials with inhibitors of the PD-1/PD-L1 immune checkpoint in ovarian cancer have shown a comparable response of around 10–15% in patients with mostly considerable prior treatment. However, the treatment effects observed in these patients, some of which were long-lasting, are encouraging. Another insight from these trials is the inadequate prediction of treatment success based solely on PD-L1 expression.

Combined treatment with chemotherapy and immune checkpoint inhibitors

The only combined treatments with immune checkpoint inhibitors in ovarian cancer studied at phase III level to date have been in combination with or as maintenance following chemotherapy (▶ Table 2). Against the backdrop of the immunomodulatory effect of many chemotherapeutics, this also makes sense, especially in first-line therapy as part of an “all-in” concept [3]. Clinical studies also confirm in ovarian cancer that platinum-based chemotherapy results in activation of an IFN response with increased immune infiltration of the tumour by CD4- and CD8-positive T cells, a reduction in the number of FOXP3-positive regulatory T cells, and an upregulation of PD-L1 [114,131,132]. Since these effects may be greatest especially during chemotherapy, the addition of the immune checkpoint inhibitor should therefore take place early.

However, this concept has not yet been confirmed in clinical trials and the addition of an immune checkpoint inhibitor has not resulted in any benefit.

The JAVELIN-Ovarian-100 trial (NCT02718417) studied the use of the anti-PD-L1 antibody avelumab either as maintenance treatment following or combined with first-line carboplatin/paclitaxel chemotherapy (n = 998). About 30% of patients had undergone surgery without residual tumour, and about 40% had received neoadjuvant chemotherapy. The trial was terminated prematurely because there was no benefit with regard to the primary endpoint PFS. Patients in the avelumab maintenance therapy arm had worse PFS than those in the control arm (HR 1.43; 95% CI 1.05–1.95; more deaths) [133]. Neither stratification by PD-L1 status, BRCA mutation nor CD8 expression was able to identify a subgroup benefiting from therapy [133].

The IMagyn050 trial (NCT03038100) tested the addition of the anti-PD-L1 antibody atezolizumab to first-line carboplatin/paclitaxel/bevacizumab therapy. Atezolizumab was already initiated in parallel with chemotherapy and then continued in parallel with bevacizumab. Here, too, the primary endpoint (PFS) was not met [5]. Overall survival, albeit with very early data, also showed no improvement so far with the addition of the anti-PD-L1 antibody. As the only significant subgroup, patients whose tumours had more than 5% PD-L1-positive immune cells (about 20% of the study population) experienced a PFS benefit from atezolizumab (HR 0.64; 95% CI 0.43–0.96) [5]. Future biomarker trials on this population are expected.

The JAVELIN Ovarian 200 trial (NCT02580058, n = 566) examined the effect of combined treatment with avelumab and pegylated liposomal doxorubicin (PLD) in platinum-resistant/refractory recurrent ovarian cancer [135]. 48% of patients received second line of treatment, the remainder following two or three previous lines of treatment. Only in the PD-L1-positive subgroup did the combined treatment demonstrate some improvement over PLD monotherapy for both PFS and OS [135].

Combined treatment with immune checkpoint and PARP inhibitors

The essential rationale for combined treatment with PD-1/PD-L1 and PARP inhibitors (PARPi) is the ability of PARP inhibitors to induce or at least enhance an anti-tumour immune response [137,138] (▶ Fig. 2). The original explanation was mainly the emergence of neoantigens or an increased tumour mutation burden...
Table 2  Phase III trials on the combined treatment with immune checkpoint blockade and chemotherapy in advanced ovarian cancer.

<table>
<thead>
<tr>
<th>Trial</th>
<th>NCT02718417 (JAVELIN Ovarian 100)</th>
<th>NCT03038100 (IMagyn050)</th>
<th>NCT02580058 (JAVELIN Ovarian 200)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune checkpoint inhibitor used</td>
<td>Avelumab</td>
<td>Atezolizumab</td>
<td>Avelumab</td>
</tr>
<tr>
<td>Targeted ICB structure</td>
<td>PD-L1</td>
<td>PD-L1</td>
<td>PD-L1</td>
</tr>
<tr>
<td>Arms</td>
<td>A) 6 × carboplatin/paclitaxel → avelumab for 24 months</td>
<td>A) 6 × carboplatin/paclitaxel/bevacizumab + placebo → maintenance with bevacizumab and placebo</td>
<td>A) Avelumab with PLD + B) Avelumab + PLLD + C) PLD</td>
</tr>
<tr>
<td>Study design</td>
<td>Multicentre, randomised (1:1:1), open</td>
<td>Multicentre, randomised (1:1), double-blind</td>
<td>Multicentre, randomised (1:1:1), open</td>
</tr>
<tr>
<td>Primary endpoint(s)</td>
<td>PFS</td>
<td>PFS, OS</td>
<td>PFS, OS</td>
</tr>
<tr>
<td>No. of patients (n)</td>
<td>998</td>
<td>1301</td>
<td>566</td>
</tr>
<tr>
<td>Population</td>
<td>First-line therapy FIGO III–IV, ECOG PS 0–1, after debulking or as neoadjuvant therapy (31.6% surgery without macroscopic residual tumour)</td>
<td>First-line therapy FIGO III–IV, ECOG PS 0–2, after debulking (75%) or as neoadjuvant therapy/interval debulking (25%) (7.4% surgery without macroscopic residual tumour)</td>
<td>Platinum-resistant/refractory recurrence ≤ 3 prior therapies no prior therapy in Pt-resistant recurrence</td>
</tr>
<tr>
<td>Histology</td>
<td>76% high-grade serous 6.2% low-grade serous 5.5% clear cell 3.2% endometrioid 8.7% other</td>
<td>76% high-grade serous 10% low-grade serous 12% high-grade non-serous 4% clear cell</td>
<td>69% high-grade serous 4% low-grade serous 13% clear cell 3% endometrioid 10% other</td>
</tr>
<tr>
<td>Definition “PD-L1 positive”</td>
<td>≥ 1% tumour cells positive and/or ≥ 5% immune cells positive (Ventana SP263 IHC assay)</td>
<td>≥ 1% immune cells positive (Ventana SP142 IHC assay)</td>
<td>≥ 1% tumour cells positive and/or ≥ 5% immune cells positive (Ventana SP263 IHC assay)</td>
</tr>
<tr>
<td>PD-L1 status</td>
<td>48.8% PD-L1 positive 32.6% PD PD-L1 negative</td>
<td>40% PD-L1 positive 60% PD PD-L1 negative</td>
<td>57% PD-L1 positive</td>
</tr>
<tr>
<td>Median PFS</td>
<td>A) 16.8 months (HR 1.43 vs. C, p = 0.989)  B) 18.1 months (HR 1.14 vs. C, p = 0.794)  C) Median not reached</td>
<td>A) 18.4 months (HR 0.92, p = 0.28)  B) 19.5 months (HR 0.78 vs. C, p = 0.030*)  C) 3.5 months</td>
<td>A) 1.9 months (HR 1.68 vs. C, p &gt; 0.999)  B) 3.7 months (HR 0.78 vs. C, p = 0.030*)  C) 3.5 months</td>
</tr>
<tr>
<td>Overall survival (OS)</td>
<td>No difference in OS to date</td>
<td>No difference in OS to date</td>
<td>A) 11.8 months (HR 1.14 vs. C, p = 0.8)  B) 15.7 months (HR 0.89 vs. C, p = 0.21)  C) 13.1 months</td>
</tr>
<tr>
<td>Median PFS (PD-L1 positive)</td>
<td>A) Median not met (HR 1.23 vs. C, p = 0.357)  B) Median not met (HR 0.98 vs. C, p = 0.918)  C) Median not met</td>
<td>A) 18.5 months (HR 0.80, p = 0.038*)  B) 20.8 months (HR 0.80, p = 0.038*)  C) Median not met</td>
<td>A) 1.9 months (HR 1.45 vs. C, p = 0.030)  B) 3.7 months (HR 0.65 vs. C, p = 0.0149)  C) 3.0 months</td>
</tr>
<tr>
<td>Median PFS (PD-L1 negative)</td>
<td>A) 16.8 months (HR 1.02 vs. C, p = 0.950)  B) 13.9 months (HR 1.36 vs. C, p = 0.232)  C) Median not met</td>
<td>A) 18.5 months (HR 0.80, p = 0.038*)  B) 20.8 months (HR 0.80, p = 0.038*)  C) Median not met</td>
<td>A) 1.9 months (HR 1.45 vs. C, p = 0.030)  B) 3.7 months (HR 0.65 vs. C, p = 0.0149)  C) 3.0 months</td>
</tr>
</tbody>
</table>

References: Ledermann et al. [133] Moore et al. [5] Pujade-Lauraine et al. [135]

* did not meet predefined level of significance

Abbreviations: ECOG PS = Eastern Co-operative Oncology Group Performance Status, ICB = immune checkpoint blockade, ICH = immunohistochemistry, HR = hazard ratio, OS = overall survival, PD-L1 = programmed cell death ligand 1, PLD = pegylated liposomal doxorubicin, PFS = progression-free survival
due to the PARPi-induced reduced ability of DNA repair: especially in tumours that already have a homologous recombination (HR) defect, e.g., due to mutations in one of the BRCA genes, additional PARP inhibition leads to an increase in the already increased neoantigen burden [139, 140]. Increased TMB, on the other hand, is a robust predictor of response to immune checkpoint inhibition [14]. However, the limited clinical data available to date demonstrate no significant correlation between BRCA1/2 mutation and improved response to immune checkpoint inhibition in ovarian cancer.

Numerous recent papers have shown that PARP inhibitors and BRCA mutations not only induce neoantigens but also activate independent mechanisms improving the immune response to the tumour [46, 141–145] (Fig. 2). Incomplete DNA repair results in the accumulation of double-stranded DNA fragments in the cytosol of the tumour cell. This cytosolic dsDNA is recognised by the cyclic cGMP-AMP synthase (cGAS), which then produces cGAMP and thus activates the STING signalling pathway ("stimulator of interferon genes"). This STING activation is accompanied by phosphorylation of the transcription factors TBK1 and IRF3, which, together with activation of the NF-κB pathway, leads to secretion of the lymphocyte-recruiting chemokines CCL5 and CXCL10 [145]. This cellular process, originally intended for viral infections, ensures increased recruitment of tumour-suppressive lymphocytes such as T cells or NK cells into the tumour microenvironment [46, 141–144, 146]. In preclinical models of ovarian cancer and TNBC, the PARPi effect even depended on this STING activation [46, 143]. Studies of the tumour genome of BRCA-mutated vs. non-mutated tumours have revealed that this process is actually relevant in patients as well: CXCL10 was identified as one of the most upregulated genes [147–149].

Moreover, cGAS/STING activation by PARP inhibitors induces PD-L1 expression in the tumour microenvironment [144, 150]. This mechanism may also explain the increased PD-L1 expression observed in BRCA-mutated tumours [119, 151]. Other mechanisms may also play a role here [152, 153]. Since the chemokines induced by PARPi/STING (CCL5, CXCL10) are necessary for anti-PD-1/PD-L1 therapy to work [39, 45], this mechanism provides another strong rationale for combining PARP and immune checkpoint inhibitors [145].

The therapeutic synergism was also confirmed preclinically in ovarian cancer mouse models both with and without BRCA mutation [46, 142, 154]. In addition, since both groups of substances have little overlapping profiles of side effects, combined treatment should also be tolerated clinically.

So far, three trials have studied the combination of PARP inhibitor and an anti-PD-1/PD-L1 antibody (Table 3). In the MEDIOLA trial, the combination of olaparib and durvalumab (anti-PD-L1) was initially assessed in a population of 34 patients solely with BRCA germline mutations and recurrent platinum-sensitive ovarian cancer [155]. The overall response rate (ORR) was 72% and 22% achieved complete remission. Although difficult to answer in such a small population, ORR was not dependent on PD-L1 status or lymphocytic infiltration in the tumour. Whether the high response rate can actually be attributed to the synergistic action of olaparib and durvalumab must be examined in further trials because olaparib also achieved response rates of around 72% in the comparable population of the SOLO3 trial, with a rate of complete remissions comparable to the MEDIOLA trial [157]. In both trials, the response rate was better in earlier lines of therapy. The median PFS was 11.1 months in the MEDIOLA study and 14.3 months in the SOLO3 study. Even though by their very nature cross-trial comparisons are problematic, the question of synergism arises here, at least in BRCA-mutated recurrent ovarian cancer.

Much more promising, however, are the outcomes of this combination in the BRCA wild-type population of the MEDIOLA trial [156]. In the platinum-sensitive population with little prior treatment, the combined treatment showed response rates of 34%. The addition of the anti-VEGF antibody bevacizumab dramatically increased this to 87% with a PFS of 14.7 months [156]. Here, one may currently assume a synergistic effect of this triple combination, which will now be assessed in numerous phase III trials with different PARP and immune checkpoint inhibitors. The DUO-O trial (AGO-OVAR23/ENGOT-ov46/NCT03737643) is studying the role of durvalumab and olaparib as an add-on to first-line carboplatin/paclitaxel/bevacizumab therapy, mostly in the BRCA wild-type population. The FIRST trial (AGO-OVAR24/ENGOT-ov44/NCT03602859) is similarly examining the combination of dostarlimab and niraparib. KEYLYNK-001 (ENGOT-ov43, NCT03740165) is assessing the combination of pembrolizumab and olaparib as add-on to first-line chemotherapy and bevacizumab in patients without BRCA mutations. Other trials in the relapse setting include the ANITA trial (AGO-OVAR23.33, NCT03598270; atezolizumab and niraparib) and the AGO-OVAR22.29 trial (NCT03353831; atezolizumab and bevacizumab).

The TOPACIO trial studied a combination of pembrolizumab and niraparib in the platinum-resistant recurrent setting [8]. Cancers both with and without BRCA mutations were eligible. The overall response rate was 18% (5% complete remission). This did not depend on BRCA mutation status or HRD (homologous recombination defect as a marker of DNA repair that is also impaired outside BRCA1/2). On the contrary, 5 of the 8 patients responding to therapy for more than 6 months had platinum-resistant/refractory BRCA-non-mutated cancer. Due to the single-arm design, only cross-trial comparisons can help assess the outcomes: The overall response rate of 19% in the platinum-resistant BRCA wild-type population is significantly higher than the figures from trials with PARPi as monotherapy reporting a response rate of 0–5% [159, 160]. It also exceeds the response rates of nearly 10% of pembrolizumab as monotherapy in the KEYNOTE-100 trial [125]. On the other hand, in the BRCA-mutated population of the TOPACIO trial (response rate 18%) there was no improvement compared to other trials with PARPi as monotherapy reporting response rates of 0–14% (platinum-refractory) or 25–30% (platinum-resistant), such as the ARIEL2 trial [161, 162].
findings need to be validated in other populations receiving similar therapies.

Another trial (NCT02484404) investigated the combination of olaparib and durvalumab from the MEDIOLA trial, this time in a mixed, but mainly platinum-resistant (86%, < 6 months), mainly BRCA-non-mutated population of 35 patients with significant prior treatment [7]. The overall response rate was 14% (0% complete remission). There was no dependence on PD-L1 status, but a significantly better numerical response rate in the BRCA-mutated group (3/8 patients vs. 2/27 patients).

Table 3: Trials on combined treatment with immune checkpoint and PARP inhibitors.

<table>
<thead>
<tr>
<th>Trial</th>
<th>NCT02657889 (TOPACIO/KEYNOTE-162)</th>
<th>NCT02734004 (MEDIOLA)</th>
<th>NCT02734004 (MEDIOLA)</th>
<th>NCT02484404</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combined treatment</td>
<td>Niraparib + pembrolizumab</td>
<td>Olaparib + durvalumab</td>
<td>Olaparib + durvalumab + bevacizumab</td>
<td>Olaparib + durvalumab</td>
</tr>
<tr>
<td>Targeted ICB structure</td>
<td>PD-1</td>
<td>PD-L1</td>
<td>PD-L1</td>
<td>PD-L1</td>
</tr>
<tr>
<td>Dosing</td>
<td>Niraparib 200 mg qd Pembrolizumab 200 mg q21</td>
<td>Olaparib 300 mg bid after 4 weeks durvalumab 1500 mg q28</td>
<td>Olaparib 300 mg bid after 4 weeks durvalumab 1500 mg q28 + bevacizumab 10 mg/kg q14</td>
<td>Olaparib 300 mg bid Durvalumab 1500 mg q28</td>
</tr>
<tr>
<td>Phase</td>
<td>Phase I/II (pooled)</td>
<td>Phase I/II</td>
<td>Phase II</td>
<td>Phase II</td>
</tr>
<tr>
<td>Study design</td>
<td>multicentre, open, single-arm</td>
<td>multicentre, open, single-arm</td>
<td>multicentre, open, single-arm</td>
<td>single-centre, open, single-arm</td>
</tr>
<tr>
<td>No. of patients</td>
<td>62 (60 analysed)</td>
<td>66 (64 analysed)</td>
<td>31</td>
<td>35</td>
</tr>
<tr>
<td>Population</td>
<td>Pt-resistant recurrence (response &gt; 6 months to first-line Pt) 79% tBRCA-WT 18% tBRCA-mutated 35% HRD positive (Myriad)</td>
<td>Pt-sensitive 50% gBRCA-WT 50% gBRCA-mutated</td>
<td>Pt-sensitive 100% gBRCA-WT</td>
<td>86% Pt-resistant (&lt; 6 months) 77% BRCA-WT 23% BRCA-mutated 20% HRD positive (BROCA-HR)</td>
</tr>
<tr>
<td>Prior therapies</td>
<td>1–5 (median 3) gBRCA-mutated: 1–4 + lines (median 2) gBRCA-WT: 1–2 lines (median 1)</td>
<td>1–2 lines (median 1)</td>
<td>52% ≥ 4 lines (median 4)</td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td>not reported</td>
<td>81% (26/32) serous 19% (6/32) non-serous not reported for gBRCA-WT</td>
<td>not reported</td>
<td>88% (31/35) high-grade serous 9% (3/35) endometrioid 3% (1/35) mucinous</td>
</tr>
<tr>
<td>PD-L1 status</td>
<td>56% PD-L1 positive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORR</td>
<td>18% (11/60)</td>
<td>53% (23/32)</td>
<td>87% (27/31)</td>
<td>14% (5/35)</td>
</tr>
<tr>
<td>CR</td>
<td>5% (3/60)</td>
<td>22% (7/32 gBRCA-mutated)</td>
<td>not reported</td>
<td>0% (0/35)</td>
</tr>
<tr>
<td>ORR (BRCAmut)</td>
<td>18% (2/11)</td>
<td>72% (23/32)</td>
<td>37% (3/8)</td>
<td></td>
</tr>
<tr>
<td>ORR (BRCA-WT)</td>
<td>19% (9/47)</td>
<td>34.4% (11/32)</td>
<td>7% (2/27)</td>
<td></td>
</tr>
<tr>
<td>ORR (PD-L1 positive)</td>
<td>21% (7/33)</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>ORR (PD-L1 negative)</td>
<td>10% (2/21)</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>ORR (HRD positive)</td>
<td>14% (3/21)</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>ORR (HRD negative)</td>
<td>19% (6/32)</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>DCR</td>
<td>65% (39/60) gBRCA-mutated: 66% gBRCA-WT: 28%</td>
<td>77% (24/31)</td>
<td>71% (25/35)</td>
<td></td>
</tr>
<tr>
<td>PFS</td>
<td>3.4 months (95% CI 2.1–5.1 months)</td>
<td>11.1 months (95% CI 8.2–15.9 months) 5.5 months (95% CI 3.6–7.5 months)</td>
<td>14.7 months (95% CI 10.0–18.1 months)</td>
<td>3.9 months (95% CI 2.0–7.25 months)</td>
</tr>
</tbody>
</table>

References

Konstantinopoulos et al. [8] Drew et al. [155, 156] Drew et al. [156] Lampert et al. [7]
however, that despite a heavily pretreated study population, long-lasting remissions of up to 2 years were also seen in platinum-resistant, BRCA-non-mutated tumours [7].

The latter trial also conducted an extensive biomarker study by obtaining tumour and serum samples from 20 patients before starting therapy and after 15 days [7]. Both the preclinically postulated increase in tumour mutational burden and the induction of interferon response were studied. Altogether, all samples showed a low mutational burden of < 5 somatic mutations/Mb, irrespective of the BRCA mutation status. PARP inhibitor therapy did not increase this TMB, although here the rather short period between the sample collections (15 days) may also have been too short to detect any effects. Tumour mutational burden was not predictive of response to immune checkpoint blockade. The study also confirmed the preclinically proven induction of an IFN response with the upregulation of IFN-γ, the CXCR3 chemokines CXCL9 and CXCL10, CCL5, the induction of PD-L1, and the increased accumulation of tumour-infiltrating lymphocytes. IFN-γ serum level elevation was predictive of treatment response, as was the immunoreactive HGSOC subtype [24].

Looking at the trial outcomes available so far, it appears that the combination of PARP and immune checkpoint inhibitors demonstrates the preclinically assumed synergistic effect, especially in the BRCA wild-type population. It may be further improved by the addition of an anti-angiogenic agent [156, 158, 164].

**Immune checkpoint inhibitors combined with other immunotherapies**

Approaches in immunotherapy that induce a specific immune response by the adaptive immune system, such as adoptive T cell transfer or CAR T cell therapy, have already shown some efficacy in ovarian cancer [165, 166]. Since in these therapies anergy of the immune effector cells involved may also be induced by immune checkpoints such as the PD-1/PD-L1 system, ICB could also be a promising combination partner for improving therapeutic success [167].

**Conclusions**

Despite success in other malignancies, the clinical response rates of immune checkpoint blockade in ovarian cancer have so far been disappointing and limited to only a few patients. The combination of immune checkpoint and PARP inhibition would seem to make sense and shows a possible benefit, especially in the BRCA wild-type population, presumably because it is precisely in this population that the immunostimulatory activity of PARP inhibitors comes into play. All in all, the few trial data available so far suggest that the response is better, in early lines of therapy. In the future, immune checkpoint blockade could also be useful in other immunotherapy approaches, such as adoptive T cell transfer and CAR T cell therapy, where the induced adaptive immune response can be further disinhhibited by the ICB.

Further research is now warranted to search for appropriate biomarkers to identify subpopulations that will benefit, and on the other hand, to identify other combination partners that can induce an immune response against ovarian cancer. The phase III trials currently underway, in particular on the triple combination of ICB, PARPi and anti-angiogenic therapy, will hopefully secure ICB a role in the treatment of advanced ovarian cancer.

**Acknowledgements**

The author would like to thank the Deutsche Forschungsgemeinschaft (BR4733/1-3, BR4733/2-1, BR4733/3-1, BR4733/4-1) and the Wilhelm Sander Foundation (2019.085.1) for their generous support.

**Conflict of Interest**

Lecturing, travel fees and/or consulting activities for AstraZeneca, Clovis, GSK, Pfizer, PharmaMar, Roche, Tesaro, and Teva.

**References**

Bronger H. Immunology and Immune ... Geburtsh Frauenheilk 2021; 81: 1128–1144 | © 2021. The author(s).


Disis ML, Taylor MH, Kelly K et al. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol 2019; 5: 393–401. doi:10.1001/jamaoncol.2018.6258


Ledermann JA, Colombo N, Oza AM et al. Avelumab in combination with and/or following chemotherapy vs. chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 Javelin ovarian 100 trial, Gynecol Oncol 2020; 159: 13–14. doi:10.1016/j.ygyno.2020.06.025

Ledermann JA. Avelumab in combination with and/or following chemotherapy vs. chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 trial SGO-Meeting 2020. Gynecol Oncol 2020; 159 (Suppl. 1): 13–14. doi:10.1016/j.ygyno.2020.06.025


[156] Drew Y, Penson RT, O’Malley DM et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol 2020; 31: S615–S616. doi:10.1016/j.annonc.2020.08.953


